ReviewDrug discovery today2019
Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management.
Review in Drug discovery today, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Rhabdomyolysis: a narrative review.Arquivos de neuro-psiquiatria · 2026Review
- Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature.Current drug safety · 2026Review
- Drug-induced adverse events in modern pharmacotherapy: mechanisms, clinical manifestations, and implications for risk assessment and management.Frontiers in pharmacology · 2026Review
- ToxBERT: an explainable AI framework for enhancing prediction of adverse drug reactions and structural insights.Journal of pharmaceutical analysis · 2025Article
- Drug-Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources.Clinical pharmacology and therapeutics · 2025Article
- An Atypical Case of Rhabdomyolysis Following an Atypical Antidepressant Overdose.Journal of clinical medicine · 2025Article
- Drug-induced cytotoxicity prediction in muscle cells, an application of the Cell Painting assay.PloS one · 2025Article
- Intramuscular heroin-induced severe rhabdomyolysis and acute kidney injury-a case report.Oxford medical case reports · 2024Article
- Advancing Adverse Drug Reaction Prediction with Deep Chemical Language Model for Drug Safety Evaluation.International journal of molecular sciences · 2024Article
- Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system.Frontiers in pharmacology · 2024Article
- Article
- Unraveling Structural Alerts in Marketed Drugs for Improving Adverse Outcome Pathway Framework of Drug-Induced QT Prolongation.International journal of molecular sciences · 2023Article
- Mini Review of Biochemical Basis, Diagnosis and Management of Crush Syndrome.Acta medica Lituanic · 2023Review
- Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis.The American journal of tropical medicine and hygiene · 2020Article
- Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data.Frontiers in pharmacology · 2020Article
- Colchicine-Induced Rhabdomyolysis: Clinical, Biochemical, and Neurophysiological Features and Review of the Literature.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Drug-induced rhabdomyolysis (DIR) is an idiosyncratic and fatal adverse drug reaction (ADR) characterized in severe muscle injuries accompanied by multiple-organ failure. Limited knowledge regarding the pathophysiology of rhabdomyolysis is the main obstacle to developing early biomarkers and prevention strategies. Given the lack of a centralized data resource to curate, organize, and standardize widespread DIR information, here we present a Drug-Induced Rhabdomyolysis Atlas (DIRA) that provides DIR-related information, including: a classification scheme for DIR based on drug labeling information; postmarketing surveillance data of DIR; and DIR drug property information. To elucidate the utility of DIRA, we used precision dosing, concomitant use of DIR drugs, and predictive modeling development to exemplify strategies for idiosyncratic ADR (IADR) management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.